Clinicopathological Features and Prognosis of Resected Pancreatic Ductal Adenocarcinoma Patients with Claudin-18 Overexpression
Journal of Clinical Medicine · 19.08.2023 · 12 (16) · 5394
DOI: 10.3390/jcm12165394 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 19.08.2023. Verfasst von Sejun Park und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Department of Internal Medicine, The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul 06591, Republic of …. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Claudin-18.2 (CLDN18.2) is specifically expressed in pancreatic precancerous lesions and pancreatic ductal adenocarcinoma (PDAC). We assessed the clinical characteristics of patients with CLDN18.2-overexpressing pancreatic cancer to identify patients who might benefit from CLDN18-targeted treatment. A total of 130 patients with surgically resected PDAC were investigated for the immunohistochemical expression of claudin-18 (CLDN18). The CLDN18 staining intensities (0–3+) and relative proportion of positive tumor cells were analyzed by two independent raters. Tumors positive for CLDN18 expression were defined as ≥80% of tumor cells with 2+ or 3+ staining intensity in a CLDN18 immunohistochemical assay. Positive CLDN18 expression was present in 41/130 (31.5%) surgically resected PDACs and the relative proportion of positive tumor cells and the staining intensity were directly correlated (p < 0.001). Positive CLDN18 expression was significantly associated with well-differentiated tumors (p < 0.001) and less regional node involvement (p = 0.045). The positive CLDN18-expressing group showed no statistical difference in median overall survival (17.4 months vs. 20.6 months, p = 0.770) compared to the negative CLDN18-expressing group. Distant nodal metastasis was more frequent in the positive CLDN18-expressing group (p = 0.011). CLDN18 is frequently expressed in PDAC, and high CLDN18-expressing PDACs showed some different clinicopathologic characteristics. High CLDN18 expression was not associated with prognosis in patients with surgically resected PDAC.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Medical Oncology, Department of Internal Medicine, The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul 06591, Republic of Korea.
- Department of General Surgery, The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul 06591, Republic of Korea.
- Department of Pathology, The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul 06591, Republic of Korea.
- Department of Pathology, National Medical Center, Seoul 03080, Republic of Korea.
ORCID-Profile: Sejun Park
Zitieren
APA
Park, S., Shin, K., Kim, I. H., Hong, T., Kim, Y., Suh, J., & Lee, M. (2023). Clinicopathological Features and Prognosis of Resected Pancreatic Ductal Adenocarcinoma Patients with Claudin-18 Overexpression. Journal of Clinical Medicine, 12(16), 5394. https://doi.org/10.3390/jcm12165394
Vancouver
Park S, Shin K, Kim IH, Hong T, Kim Y, Suh J, et al. Clinicopathological Features and Prognosis of Resected Pancreatic Ductal Adenocarcinoma Patients with Claudin-18 Overexpression. Journal of Clinical Medicine. 2023;12(16):5394. doi:10.3390/jcm12165394
BibTeX
@article{Park2023,
author = {Park, Sejun and Shin, Kabsoo and Kim, In-Ho and Hong, Taeho and Kim, Younghoon and Suh, Jahee and Lee, Myungah},
title = {Clinicopathological Features and Prognosis of Resected Pancreatic Ductal Adenocarcinoma Patients with Claudin-18 Overexpression},
journal = {Journal of Clinical Medicine},
year = {2023},
volume = {12},
number = {16},
pages = {5394},
doi = {10.3390/jcm12165394}
}
EUVIMED